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Introduction
Breast cancer can almost be considered an epidemic in today’s 
world.  It is the most frequently occurring cancer in women 
worldwide. (Li, 2016)  It has become evident that breast can-
cer diagnoses have increased because screening methods have 
become more efficient and because overall life expectancy has 
been lengthened in recent years.  In most cases, breast can-
cer is treated by removal of the tumor and surrounding areas. 
Sometimes neo-adjuvant (prior to surgery) therapy is given. 
Alternatively, treatment only begins after surgery.  Afterwards 
radiation is applied to the tumor site and surrounding areas. In 
addition, if the tumor is hormone receptor (estrogen or proges-
terone or both) positive, patients will undergo hormone ther-
apy as well as chemotherapy.  This paper will discuss radiation 
therapy and hormone therapy as a systemic treatment but will 
not cover chemotherapy.
Methods
This article was written through the analysis of various original 
research and peer reviewed journal articles.  Access was ob-
tained through PubMed and the Touro College Library.
Results and Discussion
Breast Conserving Treatment and Mastectomy
Breast cancer treatment has shifted from total mastectomy to-
ward breast conserving therapy.  From the 1970’s, studies have 
shown that breast conserving surgery with radiation have the 
same effects as the Halsted (radical) Mastectomy for tumors 
up to 5 cm. (Veronesi, et.al 2013)  When a patient with breast 
cancer undergoes breast conserving therapy, radiation of the 
breast and some surrounding areas is usually applied (Aebi, et.al 
2011).  Even after mastectomy, radiation is required if there are 
four or more lymph nodes found that ae positive for cancer.. 
There was no observed benefit from radiation in women with 
node negative disease. (EBCTCG, McGale, et.al. 2014)  Post-
mastectomy radiation is recommended if the tumor is 5 cm or 
larger, there are at least 4 positive nodes, a positive margin of 
resection, or skin involvement.  However, because of the psy-
chological effects of mastectomy, breast conserving surgery is 
now considered an acceptable form of treatment even when 
the tumor is large, as long as the breast can be reshaped.  Now, 
about 25% of women diagnosed with breast cancer undergo 
mastectomy, usually because of large tumor size, location of the 
tumor, or local recurrence following a previous breast conserv-
ing surgery. (Orecchia, 2015)
In order to reduce the psychological effects and cosmetic draw-
backs of mastectomy, the skin sparing method has been intro-
duced.  One recent development in the skin sparing method is 
nipple-sparing mastectomy which allows for the preservation of 
the nipple areola complex.  However, there has been increased 
recurrence behind the areola following nipple sparing mastec-
tomy.  Therefore, radiation is performed on patients that are 
at greater risk of recurrence.  There is no standard practice in 
patients who have an intermediate or low risk and radiation’s 
role in this case is unclear. (Orecchia, 2015)  Although further 
research is needed, this new method can open up new opportu-
nities for better methods of breast reconstruction.
Comparison of Mastectomy, Lumpectomy, and 
Lumpectomy plus Irradiation
A study was performed to see whether mastectomy, lumpec-
tomy, and lumpectomy plus irradiation had different effects on 
survival.  Follow up after 20 years showed no significant differ-
ence in survival between the group that underwent mastectomy 
as opposed to the groups that underwent lumpectomy with or 
without radiation.  This study did not show any risk of radiation 
causing cancer in the contralateral breast which is a common 
concern.  The findings at 20 years of follow up did indicate that 
lumpectomy with irradiation significantly decreases recurrence 
when compared to lumpectomy without irradiation.  However, 
perhaps, if wider margins were removed at the time of breast 
conserving surgery, the need for radiation afterwards would be 
eliminated. (Fisher, et.al. 2002)
Effects of Radiation following Breast Conserving 
Surgery
Breast conserving surgery can be performed on women with 
a less advanced stage of breast cancer by removing any micro-
scopic residual of the cancer.  However, macroscopic bits of 
the tumor can remain in the breast or nearby area; therefore 
radiation is commonly used to prevent local recurrence and dis-
tant metastases.  In one study, 10,801 women were included to 
see how radiation can reduce the risk of recurrence and death 
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including different variables, such as age, tumor size, and nodal 
status.  This study differs from previous studies in three ways. 
Firstly, it assumes that all recurrence whether it is locoregional 
or distant is related to the tumor that preceded it.  Therefore all 
recurrence is considered as first recurrence.  Secondly, previous 
studies obtained follow up results for 10 years, and this one 
goes up to 15 years.  Lastly, previous studies considered death 
of unknown causes within the first 10 years to be attributed 
to breast cancer, but this study attributes it to other causes. 
(EBCTCG, Darby, et.al. 2011). 
When radiation was applied after breast conserving surgery, the 
10-year risk of recurrence dropped to 19.3% as opposed to 
35.0% in women that did not undergo radiotherapy.  The risk 
reduction in this case is 15.7% for women who had radiother-
apy following breast conserving surgery.  Three quarters of the 
recurrence in those that had no radiation therapy was of a local 
nature while fewer than half of those in the radiation group 
had a locoregional recurrence.  In addition, radiation reduced 
the risk of cancer related mortality to 3.8% in 15 years, which 
suggests that for every 4 recurrences avoided due to radiation, 
one death was prevented.
Radiation halved the risk of annual first recurrence and it re-
duced cancer related death by a sixth.  However, mortality with-
out recurrence (death from other causes) was slightly higher 
during the first 10 years in the radiation following breast con-
serving surgery group than those who did not have radiation. 
The higher death rate in the radiation group can be attributed 
to the toxicity of the radiation.  However, this is not considered 
significant because it is such a minuscule percentage.  On aver-
age, including all the women of all the different groups (node 
status, age, endocrine receptor responsiveness, etc.), during a 
15-year period, one death was avoided for every four recur-
rences avoided by year 10.  
This study considers any instance of recurrence, no matter 
where it occurs, as a first event rather than only considering 
locoregional recurrence as a first event as other studies have 
done.  This gives more accurate results than previous studies. 
Different kinds of recurrences cannot be ignored because radi-
ation is assumed to reduce all recurrences.  Because this study 
gathered data from patients with a wide range of risks and over-
all, radiation halved the risk of recurrence, it can be assumed 
that it will reduce the risk in future patients as well by a half. 
(EBCTCG, Darby, et.al. 2011).
Boost
After 50 Gy radiation on the breast, a 16 Gy boost is rec-
ommended except for in patients with a low risk for local 
recurrence. (Aebi, et.al 2011)  As stated previously, radiation 
prevented one death in a 15-year follow up for every four 
instances of local recurrence prevented in a 10-year follow 
up.  However, because of the intensity of the radiation, fibro-
sis frequently occurred which caused a poor cosmetic result. 
(Bartelink, et.al. 2007)  In one trial, the boost dose was lowered 
from the previously accepted 25 Gy to 16 Gy because of the 
high percentage of patient fibrosis which resulted from the in-
tensity of the boost.  There were 5,569 breast cancer patients 
who were included in the boost vs. no boost study.  The patients 
were no different from each other with respect to surgery or 
whole breast irradiation.  Local recurrence in the no boost 
group after 10 years was 4% higher than in the boost group. 
Incidence of fibrosis at 10 years was 4.4% in the boost group as 
opposed to 1.6% in the no boost group.  Although a boost of 16 
Gy was shown to decrease the rate of local recurrence in this 
study, no improvement has been discovered in disease-specific 
survival or overall survival.  However, this could be because of 
the success of salvage mastectomy which was performed on 
the no boost group when they began to exhibit signs of local 
failure.  The risk of fibrosis for those in the boost group is not 
of a significant level. (Bartelink, et.al 2015).  
The above study was done over a period of 10 years.  A different 
study was performed which included 20-year follow up for all 
patients.  This trial was performed to see if a boost dosage of 16 
Gy decreased the rate of recurrence.  A 5-year follow up study 
showed that it does decrease recurrence.  A 10-year follow up 
showed that when a boost is delivered, the rate of salvage mas-
tectomies decreases.  In the 20-year follow up, local recurrence 
was 13% in the no boost group as opposed to 9% in the boost 
group.  Incidence of fibrosis was a little bit higher (about 4%) in 
the boost group.  The cumulative percentage for salvage mas-
tectomies performed on the boost group was 6.4 vs. 10.3 for 
the no boost group.  The fact that there was no improvement 
in overall survival in the boost group seems to show that the 
boost is not needed.  However, this must be the result of the 
high rate of successful salvage mastectomies performed.  The 
boost the number of salvage mastectomies by a third. (Bartelink, 
et.al 2015)
Effects of Radiation following Mastectomy
Post mastectomy radiation is used to treat women with four 
or more positive lymph nodes to ensure complete removal of 
any residual tumor foci.  However, the role of radiation in treat-
ing women post mastectomy with one to three positive lymph 
nodes still remains uncertain.  As of now, post mastectomy ra-
diation is not given to women who have node-negative disease. 
The following study included 8,135 women who had 1 to 3 pos-
itive lymph nodes.  About 20% of the women had node-negative 
disease, 72% had node positive disease, and the nodal status for 
the remaining ones was unknown.
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Radiation therapy was shown to significantly decrease the rate 
of recurrence and breast cancer death in the group that had 
1 to 3 positive lymph nodes.  Radiation was not seen to have 
any added positive benefit in women who had node negative 
disease.  Radiation reduced the 10 year risk of recurrence in 
women with 1 to 3 positive lymph nodes from 45.7% to 34.2% 
which is an overall absolute benefit of 11.5%.  Today, radiation 
treatments cover more of the high risk areas, such as the chest 
wall.  In addition, the doses are lower than they used to be so 
the risks of radiation have decreased.  Therefore, the propor-
tional gains of radiation today are probably greater than the 
results of this study.  However, within the 20 years in which this 
study has been performed, methods of detection and treatment 
have improved; therefore the absolute benefits of radiation are 
lower than those reported in this study.  (EBCTCG, McGale, 
et.al 2014).
Intraoperative Radiotherapy
There is new research in the field of intraoperative radiother-
apy to treat many different kinds of cancers including breast 
cancer.  Instead of a few weeks or months of radiation post 
breast conserving surgery, patients can be treated with a dose 
of radiation at the surgery itself.  Although the average time of 
radiation has decreased over the last couple of years, it is still 
a strain and inconvenience on the women who must travel to 
the hospital every day for about 30 days to receive treatment. 
Another advantage of intraoperative therapy over mastectomy 
is that if recurrence occurs after breast conserving surgery and 
a mastectomy is needed, it is easier to perform it with the now 
popular method of skin and or nipple sparing procedures if no 
radiation was applied to the skin because radiation can cause 
necrosis. (Veronesi, et.al. 2013)  In addition, intraoperative radi-
ation therapy can target the cancerous tissue while protecting 
the normal tissue around the tumor. (Najafipour, et.al, 2015).
In one trial, the effects of intraoperative radiation on a number 
of different cancers was tested.  Intraoperative radiation was 
found to increase survival in patients with pancreatic cancer. 
When used on patients with early breast cancer, it was found 
to decrease life expectancy by less than a day.  Although it may 
increase operating room load, it is generally a cost effective and 
considered a safe method to treat breast cancer. (Najafipour, 
et.al, 2015)  However, more research must be done to see if this 
new method has any real advantage.
In another study, 1305 patients were randomized, 654 belonging 
to the external radiotherapy group and 651 to the intraoper-
ative group.  Only 11% had more than 4 positive nodes.  In 
this study, ipsilateral breast tumor recurrence was defined as 
“the sum of local recurrence plus 2nd ipsilateral tumors.”  Local 
recurrence was considered the recurrence of the carcinoma at 
the previous location.  Within five years of follow up, there was 
a significantly greater instance of recurrence in the intraopera-
tive radiation therapy group than in the external radiotherapy 
group.  Overall survival, however, did not differ significantly be-
tween the two groups.  Predictions are that in the future, better 
methods will be used to differentiate between patients who are 
at higher risk of recurrence and therefore need external whole 
breast irradiation or intraoperative radiation plus external ra-
diation.  (Veronesi, et.al 2013)  It must be noted that this study 
only measured 5 years which considered short term follow up 
in a study of this sort.
Testing for Endocrine and HER-2 Receptivity
Trastuzumab
Overexpression of HER2 protein occurs in 20-25% of breast 
cancers, causing high-grade tumors, increased growth rates, 
early systemic metastasis, and reduced rates of overall and dis-
ease free survival. (Slamon, et.al 2011)  Trastuzumab (Herceptin) 
is given many times in conjunction with chemotherapy, but 
it can also be given alone.  Trastuzumab does not cause the 
negative side effects that other chemotherapy medications 
are known for, such as alopecia, myelosuppression, and severe 
nausea.  However, Trastuzumab has been known to cause car-
diotoxicity in 1.4% of those to whom it was administered to. 
(Piccart-Gebhart, et.al 2005)  Various studies were performed 
to find out how much Trastuzumab actually improved disease 
free survival and whether the increase in cardiotoxicity was a 
cause for concern.
One study included 4,482 women.  Both groups received 
Trastuzumab after undergoing primary treatment (surgery, 
chemotherapy, radiation, ect.).  One group received it for one 
year, the other for two.  Patients with a history of cardiac 
trouble were excluded from this study.  The study shows that 
Trastuzumab given after primary treatment reduces the rate of 
recurrence by 50%.  It does not seem to make a difference what 
type of chemotherapy is received.  The risk of cardiotoxicity is 
low; however, it is possible that this is because there is a short 
follow up in this study.  In addition, there is a concern that lon-
ger term follow up will show that Trastuzumab does not reduce 
disease recurrence in the central nervous system. The results of 
this study indicate that one year of Trastuzumab should be used 
following primary treatment of breast cancer. (Piccart-Gebhart, 
et.al 2005).
A study was performed to see whether an anthracycline-based 
regimen increased Trastuzumab’s toxicity.  There were 3,222 
women who were divided into three groups.  One group un-
derwent an anthracycline regimen.  In the second group, the 
patients received anthracycline with Trastuzumab.  In the third 
group, the patients only received Trastuzumab.  All three groups 
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underwent an intense cardiac monitoring schedule.  A signif-
icant benefit was seen in patients who received Trastuzumab 
as opposed to patients who did not.  There were no appar-
ent differences between the two Trastuzumab goups; however 
the trial was not set up to discern a difference between them. 
Congestive heart failure occurred more often in the group that 
received anthracycline in addition to Trastuzumab.  In addition, 
treatment time is decreased when anthracycline is not given. 
(Slamon, et.al. 2007).
Hormones and their effect on Breast Cancer and 
breast cancer treatment
In the Million Women Study conducted in the UK, over 1 million 
women between the ages of 50-64 were recruited to have a 
breast screening every three years.  The women were given 
a survey to complete shortly before their screening.  (The 
questionnaire can be viewed at http://www.millionwomen-
study.org).  The purpose of the study was to see if and how 
hormone replacement therapy affects breast cancer.  In total, 
50% of the population had used hormone replacement thera-
py at some time.  The results of the study proved that recent 
or current users of hormone replacement therapy are at in-
creased risk of breast cancer.  Those using estrogen-progesto-
gen combinations have a four times greater risk than those 
using estrogen-only preparations.  However, past users of 
hormone replacement therapy have almost no increased risk. 
In all, hormone replacement therapy results in 5 to 6 more 
cancers per 1,000 women with 5 years use and 15-19 extra 
cancers per 1,000 women with 10 years use. (Million Women 
Study Collaborators, 2003).
The Million Women Study, because of its large number of par-
ticipants and span of time, has been the source of much con-
troversy.  It has been pointed out the women who participated 
in the study are not a good sampling of the general population 
because women that use hormone replacement therapy are 
more likely to be concerned about their risk of cancer and go 
for a mammogram. (Eden, 2010)  However, the Million Women 
Study represented 53% of the population, so although this may 
be 53% of the population that is more likely to be affected by 
hormone replacement therapy, over half a population is a good 
indication of the rest of the population.  
Hormone Therapy
Soon after a patient is diagnosed with breast cancer, she is test-
ed to see whether her tumor is hormone receptor positive of 
negative, defined by estrogen and/or progesterone receptivity. 
Accurate assessment is critical in deciding whether to treat 
with hormone therapy; however, accurate results are difficult 
to obtain.  
In the past, tumors that showed less than 10% positivity were 
not given hormone therapy because they seemed similar to pa-
tients who tested negative for hormone receptivity.  Recently, 
however, The ASCO/CAP guidelines were revised to treat 
women in the 1%-9% positivity group with hormone therapy. 
Now 3% more women are being treated with hormone thera-
py.  The problem is that although for a small minority of cases, 
hormone therapy has a good positive result on those in the 
1-9% group, physicians must consider the benefits of endocrine 
therapy versus its cost and side effects. (Yi M, et.al 2014)  The 
goal of this study, as noted above, was to show that perhaps 
the benefits of treating the 1-9% group with endocrine therapy 
do not outweigh the costs.  However, this study has limitations. 
They retroactively collected the data and because of that, the 
Estrogen receptor status is not known for certain because the 
patients obtained their diagnosis outside the facility where this 
study was performed.  In addition, the study’s limited sample 
size makes it very difficult to analyze the data based on results 
from adjuvant chemotherapy and endocrine therapy.
A later study shows that even with a very small percentage 
of Estrogen receptor positivity, adjuvant hormone therapy cut 
breast cancer mortality by a third for fifteen years.  Those who 
had hormone receptor treatment were found, initially, to have 
lower rates of recurrence than those without; however, they do 
risk relapse for up to fifteen years despite usage of Tamoxifen 
for five years. (EBCTCG, Davies, et.al. 2011).
The suppression of hormones and the target of HER2 recep-
tors is a not a new development in medicine.  Two cohorts, 
comprised of 7,178 patients, were studied to see whether 
current hormone treatment is more effective than that of the 
past.  One cohort was diagnosed recently, and the other was 
diagnosed from 1986-1992.  Relapse event was any disease re-
currence.  In all, 1,700 patients had relapsed in 9 years of follow 
up.  The result showed that the current treatments are more 
effective because they are used for longer and they are more 
efficient.  However, patients with ER+ tumors do seem to have 
a late relapse and ER- tumors have an early relapse in patients 
that were recently diagnosed. (Cossetti, et.al 2014).
Another study was performed in 1996 to see whether there 
is a difference and how significant of a difference 2 years of 
Tamoxifen makes compared to 5 years of treatment .  The re-
sults showed that 5 years was more effective.  They did not test 
past 5 years; therefore, they do not know if more than 5 years 
would be more effective. (Swedish Breast Cancer Cooperative 
Group, 1996).
Premenopausal hormone receptor positive breast cancer is 
treated by ovarian ablation or suppression.  The ovaries still 
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function in premenopausal women and they are the main site 
for hormone production.  The aromatization of androgens in 
the adrenal glands produces hormones in postmenopausal hor-
mone-receptor positive breast cancer.  Aromatase Inhibitors 
(AI’s) inhibit the production of those hormones.  AI’s fall into 
two categories:  non-steroidal and steroidal AI’s.  Across the 
board, AIs are superior to Tamoxifen.  The ovaries are only 
temporarily suppressed when women are premenopausal for 
preservation of fertility. (Li, et.al. 2016).
The Premenopause/Post-menopause treatment 
methods
Tamoxifen is the standard drug to treat hormone receptor 
positive breast cancer.  Premenopausal patients, however, are 
often resistant to Tamoxifen.  Therefore ovarian function sup-
pression medications are combined with Tamoxifen in order to 
reduce disease recurrence in pre-menopausal women.  Ovarian 
function suppression medications increase toxicity, complicating 
overall treatment regimens.  (Kim et. al, 2016).  
Two trials were performed, the Tamoxifen and Exemestane Trial 
(TEXT) and the Suppression of Ovarian Function Trial (SOFT), 
to determine whether the aromatase inhibitor Exemestane 
improved survival in premenopausal women when used in con-
junction with Tamoxifen as opposed to women treated with 
ovarian suppressors with Tamoxifen.  The combined data from 
the two studies shows that Exemestane plus ovarian suppression 
as opposed to Tamoxifen plus ovarian suppression significantly 
improved survival and decreased risk of recurrence.  (Pagani 
et. al, 2014)  However, in the SOFT study, the women who re-
mained premenopausal and had an increased risk of recurrence 
and therefore needed adjuvant chemotherapy, the addition of 
ovarian suppression treatments improved survival rates (Kim et. 
al, 2016)  Because these women received additional chemother-
apy, it is not clear whether it is the chemotherapy or the ovarian 
suppression that increased survival.
A Korean Study was performed to compare ovarian function 
suppression with Tamoxifen versus just Tamoxifen in young, 
premenopausal women who had undergone chemotherapy. 
The main purpose of this study was to compare the 5-year dis-
ease-free survival rates between the two groups.  The Korean 
Breast Cancer Society focused on this age range because al-
though South Korea has an overall smaller number of breast 
cancer diagnoses compared to the world at large, 48.7% of 
breast cancer diagnoses are in premenopausal women under 
the age of 50 which is a much higher percentage of young 
women than in other countries.
The advantage of this study over other studies is that there 
is repeated evaluation of ovarian function, which allows for 
better selection of patients that should be receiving ovarian 
function suppression treatments, avoiding unnecessary side ef-
fects.  Ovarian suppression causes menopausal symptoms which 
significantly alter the the quality of life.  These symptoms can 
lead to a lack of patient compliance and can also destroy phy-
sician-patient relationship (Kim et. al, 2016).  This study shows 
the benefit of Tamoxifen plus ovarian suppression therapy in 
premenopausal patients with Estrogen receptor positive breast 
cancer treated with chemotherapy.  This trial helps determine 
the optimal endocrine therapy needed based on ovarian func-
tion status of premenopausal patients.
Conclusion
The patient must undergo a mastectomy if reconstruction of 
the breast post breast conserving surgery is impossible or not 
feasible.  However, mastectomy is not as radical as it once was. 
Moreover, now there are new skin sparing methods, such as the 
nipple areolar sparing method which allows for a more natu-
ral reconstruction after surgery.  Post mastectomy radiation is 
given in women with 4 or more positive lymph nodes, but in 
women with 1-3, the question still remains.  Studies show that 
in women with 1-3 positive lymph nodes, recurrence is reduced 
by over 10%.
In about 75% of cases, patients undergo breast conserving sur-
gery.  Except in cases of very low risk of recurrence, patients 
must have radiation afterwards.  However, perhaps better tumor 
residue removal will be employed which can eliminate the need 
for radiation therapy.  After breast conserving surgery, radiation 
reduces risk of recurrence within 10 years from 35% to 19%, a 
significant difference.  Radiation prevents one death for every 
four recurrences prevented (a 3.8% decrease).  Radiation does 
increase toxicity; however, the percentage is so low, that they 
give radiation anyways.  However they do try to keep dosages 
low.  A radiation boost after the radiation treatment regimen 
decreases recurrence by 4% over a period of 10 years and after 
20 years.  There is no difference in overall survival between the 
group which received a boost and the one that didn’t because 
of salvage mastectomies and other retroactive treatments per-
formed.  The risk of fibrosis does increase by the same percent-
age as survival in the boost group.
Trastuzumab is given to those that test positive for HER2 ex-
pression.  Although it does increase cardiotoxicity in 1.4% of 
cases, it has less side effect than other chemotherapy medica-
tions.  However, the risk of toxicity may be low in this study 
because of a short (5 year) follow up.  A longer follow up may 
show a larger percentage of toxicity.
Hormone replacement therapy increases one’s risk of getting 
breast cancer.  Those who take an estrogen-progesterone 
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combinations have a four times greater risk of developing can-
cer than those who take estrogen only.  Each woman together 
with her doctor must decide whether the benefits outweigh the 
risks in taking hormone replacement treatment.  This treatment 
increases the quality of life for post-menopausal women; howev-
er if someone has an increased risk of developing breast cancer, 
they should not take this treatment.  The Million Women Study 
does represent most of the population.  However, sometimes 
large studies cannot take certain factors into because although 
they do divide their sample by different characteristics, there 
are too many people to be very exact and specific.
New guidelines have been set up, so now women with 1-9% 
hormone positive lymph nodes get hormone therapy.  However 
the study that proved that this change is necessary (from the 
previous about 10%) has limitiations.  Firstly, they collected the 
data retroactively, so they could not be certain that all of it 
was correct, and they had a limited sample size.  Those that are 
hormone receptor positive and take hormone therapy for five 
years do initially have decreased recurrence, but they do risk 
relapse for up to 15 years.  
In the study where a group received hormone therapy from 
1986-1992 was compared to a more recent group, it was prov-
en that hormone therapy is more effective now because the 
therapies are more efficient and they are used for longer than 
they once were.  Although those with hormone receptor pos-
itivity have a better prognosis, they are at risk for a relapse 
albeit much later than those with hormone receptor negative 
cancer.  Hopefully new research and discoveries will lead to a 
more permanent and better prognosis.  
Premenopausal women are resistant to Tamoxifen, so it is usu-
ally applied together with ovarian suppressors.  These suppres-
sors can increase toxicity, but they do improve.  As the Korean 
study noted, repeated evaluation of ovarian function can allow 
for better selection of patients which can avoid unnecessary 
side effects which lower quality of life.
All the above research shows that there is no one best method 
to treat breast cancer.  Treatment must have a multidisciplinary 
approach.  Each patient must be treated as an individual with all 
symptoms and disease specifics taken into account.
There are various limitations that studies have.  One limitation 
is that studies, by their very nature, must be performed under 
certain assumptions, like assuming that death of an unknown 
cause within 10 years is disease mortality which may or may 
not be the case.  In addition, a large sample size can cause a 
“one size fits all” attitude. Trials involving breast cancer patients 
have an advantage because there are many people who have 
breast cancer.  However because of the large study size, at times 
there is not enough specification of treatment.  One woman 
may seem to have the same diagnoses as another, but some 
important differences may not be accounted for.  For example, 
a woman who tests positive for HER2 receptor and has 8.5% 
hormone receptor positivity will be given Trastuzumab and hor-
mone therapy, but perhaps she has a risk of heart disease in her 
family and the increased cardiotoxicity will be more harmful for 
her than the average patient.  It is not enough for doctors to be 
up to date on different treatment advances, they must create a 
treatment plan that takes each individual patient’s needs, back-
ground, and overall health into account.
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